Mutabon Antidepressivo (Amitriptyline Hydrochloride, Perphenazine)

Amitriptyline Hydrochloride / Perphenazine, the active ingredient in Mutabon Antidepressivo, is a combination antidepressant and typical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of depression in adult patients, including depressive episodes with psychotic features and is prescribed by psychiatrists and primary care physicians.

GNH USA supplies Mutabon Antidepressivo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Mutabon Antidepressivo combines amitriptyline and perphenazine to address depressive disorders and associated psychotic symptoms.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Psychotic depression: alleviates depressive symptoms while controlling psychotic features. - Treatment‑resistant depression: provides an alternative when monotherapy has been insufficient. - Severe depressive episodes with agitation: helps stabilize mood and reduce agitation. - Depressive episodes with insomnia: amitriptyline component improves sleep quality.

Mutabon Antidepressivo may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to discomfort. - Constipation: slowed gastrointestinal transit. - Weight gain: increase in body weight over time. - Blurred vision: temporary visual disturbances. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Neuroleptic malignant syndrome: rare but severe reaction with fever and muscle rigidity. - Seizures: risk of convulsive episodes, especially at high doses. - Severe hypotension: marked drop in blood pressure causing fainting. - Agranulocytosis: dangerously low white blood cell count. - Hepatotoxicity: liver injury indicated by elevated enzymes.

Before prescribing Mutabon Antidepressivo, clinicians should consider several safety precautions. - Pregnancy: Category C; use only if potential benefits justify the risk. - Breastfeeding: caution advised as drug may be excreted in milk. - Elderly patients: start with low dose and monitor for anticholinergic effects. - Cardiac history: avoid in patients with known conduction disorders or recent myocardial infarction. - Concomitant CNS depressants: monitor for enhanced sedation and respiratory depression. - Storage: Store below 25°C: keep in original container, protect from moisture and light.

Mutabon Antidepressivo can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertensive crisis; must be discontinued at least 14 days prior. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase amitriptyline levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: additive dry mouth, constipation, urinary retention. - CNS depressants (alcohol, benzodiazepines): enhanced sedation and respiratory depression. - QT‑prolonging agents: combined effect may increase risk of cardiac arrhythmias.